Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-10-16

Corcept Therapeutics (CORT)

CEO Joseph Belanoff was paid $15,303,551 in fiscal year 2025, ↑ up 54.7% from fiscal year 2024 (SEC filing 0001628280-26-025735 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$15,303,551 ↑
Joseph Belanoff total, FY2025
—
CEO pay percentile vs peers
46:1
CEO-to-median pay ratio
94.08%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Joseph Belanoff (Chief Executive Officer and President), FY2025 total compensation $15,303,551 (base salary $1,182,333) [exec_comp, SEC accession 0001628280-26-025735, filed 2026-04-17]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

CORT's next annual pay disclosure, estimated April 9, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Joseph Belanoff$1,182,333$1,190,000$0$12,907,718$0$0$23,500$15,303,551
Chief Executive Officer and President
Charles Robb711,413358,000124,5005,163,0870023,5006,380,500
Chief Business Officer and Secretary
William Guyer706,387429,60017,8715,163,0870023,5006,340,445
Chief Development Officer
Sean Maduck648,860261,200111,9955,163,0870023,5006,208,642
President, Corcept Endocrinology
Atabak Mokari566,347285,00097,7335,163,0870023,5006,135,667
Chief Financial Officer and Treasurer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Joseph Belanoff$15,303,551$9,890,081$9,337,734↑ +5,413,470
Charles Robb6,380,5004,138,3713,956,718↑ +2,242,129
William Guyer6,340,445—3,856,200—
Sean Maduck6,208,6423,971,1713,908,931↑ +2,237,471
Atabak Mokari6,135,6673,857,3063,717,107↑ +2,278,361

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Corcept Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CORT reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against CORT
23 companies name CORT as a compensation peer

Each company listed discloses CORT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CORT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Joseph BelanoffCEO$15,303,551
Atabak MokariCFO$6,135,667
Charles RobbExecutive$6,380,500
Sean MaduckPresident$6,208,642
William GuyerChief Development Officer$6,340,445
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Daniel N. Swisher JrIndependent Director$762,004
David L. MahoneyIndependent Director$784,504
G. Leonard Baker JrIndependent Director$768,004
Gillian M. CannonFormer director (through FY2025)$770,504
Gregg AltonIndependent Director$787,004
James N. WilsonChair of the Board$1,292,914
Joshua M. MurrayIndependent Director$764,504
Kimberly ParkIndependent Director$764,994
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Charles RobbChief Business Officer2026-05-13A1,000$0$0CommonForm 4 ↗
Charles RobbChief Business Officer2026-05-13D5,30000CommonForm 4 ↗
Charles RobbChief Business Officer2026-05-13A1,00000CommonForm 4 ↗
Joshua M. MurrayDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
Daniel N. Swisher JrDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
James N. WilsonDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
Gregg AltonDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
G. Leonard Baker JrDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
Kimberly ParkDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
David L. MahoneyDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
James N. WilsonDirector2026-05-27A9,01100Common, indirectForm 4 ↗
Charles RobbChief Business Officer2026-05-27D60000CommonForm 4 ↗
Sean MaduckSee Remarks2026-05-27A75,0008620,250CommonForm 4 ↗
James N. WilsonDirector2026-05-27D9,01100Common, indirectForm 4 ↗
Joseph Douglas LyonSee Remarks2026-05-27D5,00065325,000CommonForm 4 ↗
James N. WilsonDirector2026-05-27D892,05600Common, indirectForm 4 ↗
Sean MaduckSee Remarks2026-05-27D75,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-05-27D54,575653,567,628Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-05-27D20,425661,351,316Common, open-market saleForm 4 ↗
Joseph K. BelanoffDirector2026-05-29A150,00000CommonForm 4 ↗
Joseph K. BelanoffDirector2026-05-29A150,00000CommonForm 4 ↗
Joseph K. BelanoffDirector2026-05-29D300,00000Common, indirectForm 4 ↗
Joseph K. BelanoffDirector2026-06-01D12,83770895,252Common, indirectForm 4 ↗
Charles RobbChief Business Officer2026-06-01A77600CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-01A6347044,659CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-01A40,00019770,400CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-01D3,93171278,103Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-06-01D40,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-01D25,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-01A25,0008206,750CommonForm 4 ↗
William GuyerChief Development Officer2026-06-01A87700CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-06-01A53700CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-01A63400CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-01D40,000702,800,004Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-06-01D21,069701,477,080Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-06-01A8777061,776CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-06-01A5377037,826CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-01A61500CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-01A6157043,321CommonForm 4 ↗
Charles RobbChief Business Officer2026-06-01A7767054,661CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-02D3957027,824CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-02D4527031,839CommonForm 4 ↗
William GuyerChief Development Officer2026-06-02D20,00000Derivative, Class A CommonForm 4 ↗
Charles RobbChief Business Officer2026-06-02D3587025,218CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-06-02D2697018,948CommonForm 4 ↗
William GuyerChief Development Officer2026-06-02D20,000711,412,000Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-06-02A20,00022433,000CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15D40,00000Derivative, Class A CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15D282165CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15D11,08181896,923Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15D9,43480754,924Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15D19,483821,593,889Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15A40,00019770,400CommonForm 4 ↗
James N. WilsonDirector2026-06-16D4,17783345,416Common, indirectForm 4 ↗
James N. WilsonDirector2026-06-16D5,82384486,633Common, indirectForm 4 ↗
David L. MahoneyDirector2026-06-17D20,000851,690,506Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-07-01D2,80189247,924Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-07-01D11,02487962,780Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-07-01A25,0008206,750CommonForm 4 ↗
Sean MaduckSee Remarks2026-07-01D25,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-07-01D11,17589998,033Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-07-07D19,048931,773,481Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-07-07A20,00022433,000CommonForm 4 ↗
William GuyerChief Development Officer2026-07-07D20,00000Derivative, Class A CommonForm 4 ↗
William GuyerChief Development Officer2026-07-07D9529489,048Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D24,16700Derivative, Class A CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D101899,032Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D3,52088310,822Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D28,460882,501,244Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15A24,16723557,291CommonForm 4 ↗
James N. WilsonDirector2026-07-15D1,97889177,007Common, indirectForm 4 ↗
James N. WilsonDirector2026-07-15D1,0798793,633Common, indirectForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D15,83300Derivative, Class A CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D7,91987687,179Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15A15,83319304,944CommonForm 4 ↗
James N. WilsonDirector2026-07-15D2,97489264,122Common, indirectForm 4 ↗
James N. WilsonDirector2026-07-15D3,96988348,223Common, indirectForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D8,267118974,951Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D80,00000Derivative, Class A CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D1,001121120,796Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D14,2221161,647,859Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D15,4771151,779,237Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D60011166,570CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D8,956107957,892Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30A80,000231,844,800CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D8,103120971,939Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D4,700113531,941Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D40010843,384CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D4,783119567,908Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D7,089117829,102Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D2,202110242,282Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D4,200106443,248Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-08-03D1,540114175,806CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-03D20,30500Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-03D20,3051152,329,075Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-08-03A20,3058167,922CommonForm 4 ↗
William GuyerChief Development Officer2026-08-04A3,7002280,105CommonForm 4 ↗
William GuyerChief Development Officer2026-08-04D3,70000Derivative, Class A CommonForm 4 ↗
William GuyerChief Development Officer2026-08-04D3,700113418,562Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-08-10D11,5301131,304,933Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-08-10A16,30022352,895CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-10D1,031115118,068Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-08-10A1,03188,526CommonForm 4 ↗
Dividend-equivalent accruals2026-08-10—1,031——1 insider, 1 accrual row
William GuyerChief Development Officer2026-08-10D16,30000Derivative, Class A CommonForm 4 ↗
William GuyerChief Development Officer2026-08-10D4,770114543,957Common, open-market saleForm 4 ↗
Charles RobbChief Business Officer2026-08-12A3,00000CommonForm 4 ↗
Charles RobbChief Business Officer2026-08-12D11,53000CommonForm 4 ↗
Charles RobbChief Business Officer2026-08-12A3,00000CommonForm 4 ↗
James N. WilsonDirector2026-08-14D4,668111520,214Common, indirectForm 4 ↗
James N. WilsonDirector2026-08-14D3,053110337,341Common, indirectForm 4 ↗
Sean MaduckSee Remarks2026-08-14D3,664114419,491CommonForm 4 ↗
James N. WilsonDirector2026-08-14D2,279113256,706Common, indirectForm 4 ↗
Sean MaduckSee Remarks2026-08-14A3,664830,301CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-14D3,66400Derivative, Class A CommonForm 4 ↗
Charles RobbChief Business Officer2026-08-17D10,0001161,162,572Common, open-market saleForm 4 ↗
Charles RobbChief Business Officer2026-08-17D12500CommonForm 4 ↗
David L. MahoneyDirector2026-08-18D40012047,855Common, open-market saleForm 4 ↗
David L. MahoneyDirector2026-08-18D7,055119838,710Common, open-market saleForm 4 ↗
David L. MahoneyDirector2026-08-18D4,984117585,478Common, open-market saleForm 4 ↗
David L. MahoneyDirector2026-08-18D91,16711810,779,367Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-08-25D30,95500Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-25A30,95511351,339CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-25D5,870126739,965Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-08-25D25,0851253,147,355Common, open-market saleForm 4 ↗
Kimberly ParkDirector2026-08-26D30,00000Derivative, Class A CommonForm 4 ↗
Kimberly ParkDirector2026-08-26D26,6851233,270,169Common, open-market saleForm 4 ↗
Kimberly ParkDirector2026-08-26D3,315122404,728CommonForm 4 ↗
Kimberly ParkDirector2026-08-26A30,00013404,700CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-01A13000CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-01A13011314,739CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-01A13800CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-01A13811315,646CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-01A16411318,594CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-09-01A13800CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-09-01A13811315,646CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01D25,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01A15000CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01A25,0008206,750CommonForm 4 ↗
William GuyerChief Development Officer2026-09-01A16400CommonForm 4 ↗
William GuyerChief Development Officer2026-09-01A16411318,594CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01D2,281116263,711Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-09-01D10,9891151,260,568Common, open-market saleForm 4 ↗
Charles RobbChief Business Officer2026-09-01A16400CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01A15011317,007CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01D11,7301141,336,459Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D58,33300Derivative, Class A CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D23,6001092,580,674Common, open-market saleForm 4 ↗
Charles RobbChief Business Officer2026-09-02D9111310,318CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D23,7701112,631,349Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D10211311,565CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D1,537111171,181Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-02D721138,163CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D5,621115644,042Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D1,606114182,632Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D974112109,474Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02A58,333221,261,743CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-09-02D10211311,565CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-02D11711313,265CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D1,225115141,413Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14D2,59600Derivative, Class A CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14A2,5961129,465CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14D2,188114249,686Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14A7,40414100,398CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14D7,40400Derivative, Class A CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14D7,812113885,261Common, open-market saleForm 4 ↗
James N. WilsonDirector2026-09-15D6,800110749,835Common, indirectForm 4 ↗
James N. WilsonDirector2026-09-15D40011144,335Common, indirectForm 4 ↗
James N. WilsonDirector2026-09-15D2,800112312,771Common, indirectForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-16D29610129,843CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-17A17,4938144,667CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-17D17,49300Derivative, Class A CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-24A5,00000CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-24A5,00000CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-24D17,10000CommonForm 4 ↗
Dividend-equivalent accruals2026-10-01—1,223——2 insiders, 2 accrual rows
Sean MaduckSee Remarks2026-10-01A41383,416CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-01D81011593,473Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-01A8101410,984CommonForm 4 ↗
Sean MaduckSee Remarks2026-10-01D41311647,717Common, open-market saleForm 4 ↗
Justin Frederick GunnSee Remarks2026-10-01A100,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-10-02D24,58700Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-10-02D8,7441171,019,143Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-10-02D15,8431161,839,741Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-10-02A24,5878203,334CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-10-02D8,33300Derivative, Class A CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-10-02D5,147117600,063Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-10-02D2,086116241,412Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-10-02D1,100115125,973Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-10-02A8,33322180,243CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02D5,83300Derivative, Class A CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02D3,35700Derivative, Class A CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02D4,744117552,869Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02D4,446116514,389Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02A5,83319112,344CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02A3,3571445,521CommonForm 4 ↗
James N. WilsonDirector2026-10-15D30011634,889Common, indirectForm 4 ↗
James N. WilsonDirector2026-10-15D3,046115351,476Common, indirectForm 4 ↗
James N. WilsonDirector2026-10-15D6,654114761,717Common, indirectForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 200 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Charles RobbChief Business Officer2026-05-13A1,000$0$0CommonForm 4 ↗
Charles RobbChief Business Officer2026-05-13D5,30000CommonForm 4 ↗
Charles RobbChief Business Officer2026-05-13A1,00000CommonForm 4 ↗
Joshua M. MurrayDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
Daniel N. Swisher JrDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
James N. WilsonDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
Gregg AltonDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
G. Leonard Baker JrDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
Kimberly ParkDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
David L. MahoneyDirector2026-05-21A12,50000Derivative, Class A CommonForm 4 ↗
James N. WilsonDirector2026-05-27A9,01100Common, indirectForm 4 ↗
Charles RobbChief Business Officer2026-05-27D60000CommonForm 4 ↗
Sean MaduckSee Remarks2026-05-27A75,0008620,250CommonForm 4 ↗
James N. WilsonDirector2026-05-27D9,01100Common, indirectForm 4 ↗
Joseph Douglas LyonSee Remarks2026-05-27D5,00065325,000CommonForm 4 ↗
James N. WilsonDirector2026-05-27D892,05600Common, indirectForm 4 ↗
Sean MaduckSee Remarks2026-05-27D75,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-05-27D54,575653,567,628Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-05-27D20,425661,351,316Common, open-market saleForm 4 ↗
Joseph K. BelanoffDirector2026-05-29A150,00000CommonForm 4 ↗
Joseph K. BelanoffDirector2026-05-29A150,00000CommonForm 4 ↗
Joseph K. BelanoffDirector2026-05-29D300,00000Common, indirectForm 4 ↗
Joseph K. BelanoffDirector2026-06-01D12,83770895,252Common, indirectForm 4 ↗
Charles RobbChief Business Officer2026-06-01A77600CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-01A6347044,659CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-01A40,00019770,400CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-01D3,93171278,103Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-06-01D40,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-01D25,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-01A25,0008206,750CommonForm 4 ↗
William GuyerChief Development Officer2026-06-01A87700CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-06-01A53700CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-01A63400CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-01D40,000702,800,004Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-06-01D21,069701,477,080Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-06-01A8777061,776CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-06-01A5377037,826CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-01A61500CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-01A6157043,321CommonForm 4 ↗
Charles RobbChief Business Officer2026-06-01A7767054,661CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-02D3957027,824CommonForm 4 ↗
Sean MaduckSee Remarks2026-06-02D4527031,839CommonForm 4 ↗
William GuyerChief Development Officer2026-06-02D20,00000Derivative, Class A CommonForm 4 ↗
Charles RobbChief Business Officer2026-06-02D3587025,218CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-06-02D2697018,948CommonForm 4 ↗
William GuyerChief Development Officer2026-06-02D20,000711,412,000Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-06-02A20,00022433,000CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15D40,00000Derivative, Class A CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15D282165CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15D11,08181896,923Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15D9,43480754,924Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15D19,483821,593,889Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-06-15A40,00019770,400CommonForm 4 ↗
James N. WilsonDirector2026-06-16D4,17783345,416Common, indirectForm 4 ↗
James N. WilsonDirector2026-06-16D5,82384486,633Common, indirectForm 4 ↗
David L. MahoneyDirector2026-06-17D20,000851,690,506Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-07-01D2,80189247,924Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-07-01D11,02487962,780Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-07-01A25,0008206,750CommonForm 4 ↗
Sean MaduckSee Remarks2026-07-01D25,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-07-01D11,17589998,033Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-07-07D19,048931,773,481Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-07-07A20,00022433,000CommonForm 4 ↗
William GuyerChief Development Officer2026-07-07D20,00000Derivative, Class A CommonForm 4 ↗
William GuyerChief Development Officer2026-07-07D9529489,048Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D24,16700Derivative, Class A CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D101899,032Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D3,52088310,822Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D28,460882,501,244Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15A24,16723557,291CommonForm 4 ↗
James N. WilsonDirector2026-07-15D1,97889177,007Common, indirectForm 4 ↗
James N. WilsonDirector2026-07-15D1,0798793,633Common, indirectForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D15,83300Derivative, Class A CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15D7,91987687,179Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-15A15,83319304,944CommonForm 4 ↗
James N. WilsonDirector2026-07-15D2,97489264,122Common, indirectForm 4 ↗
James N. WilsonDirector2026-07-15D3,96988348,223Common, indirectForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D8,267118974,951Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D80,00000Derivative, Class A CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D1,001121120,796Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D14,2221161,647,859Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D15,4771151,779,237Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D60011166,570CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D8,956107957,892Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30A80,000231,844,800CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D8,103120971,939Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D4,700113531,941Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D40010843,384CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D4,783119567,908Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D7,089117829,102Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D2,202110242,282Common, open-market saleForm 4 ↗
Atabak MokariChief Financial Officer2026-07-30D4,200106443,248Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-08-03D1,540114175,806CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-03D20,30500Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-03D20,3051152,329,075Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-08-03A20,3058167,922CommonForm 4 ↗
William GuyerChief Development Officer2026-08-04A3,7002280,105CommonForm 4 ↗
William GuyerChief Development Officer2026-08-04D3,70000Derivative, Class A CommonForm 4 ↗
William GuyerChief Development Officer2026-08-04D3,700113418,562Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-08-10D11,5301131,304,933Common, open-market saleForm 4 ↗
William GuyerChief Development Officer2026-08-10A16,30022352,895CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-10D1,031115118,068Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-08-10A1,03188,526CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-10D1,03100Derivative, Class A CommonForm 4 ↗
William GuyerChief Development Officer2026-08-10D16,30000Derivative, Class A CommonForm 4 ↗
William GuyerChief Development Officer2026-08-10D4,770114543,957Common, open-market saleForm 4 ↗
Charles RobbChief Business Officer2026-08-12A3,00000CommonForm 4 ↗
Charles RobbChief Business Officer2026-08-12D11,53000CommonForm 4 ↗
Charles RobbChief Business Officer2026-08-12A3,00000CommonForm 4 ↗
James N. WilsonDirector2026-08-14D4,668111520,214Common, indirectForm 4 ↗
James N. WilsonDirector2026-08-14D3,053110337,341Common, indirectForm 4 ↗
Sean MaduckSee Remarks2026-08-14D3,664114419,491CommonForm 4 ↗
James N. WilsonDirector2026-08-14D2,279113256,706Common, indirectForm 4 ↗
Sean MaduckSee Remarks2026-08-14A3,664830,301CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-14D3,66400Derivative, Class A CommonForm 4 ↗
Charles RobbChief Business Officer2026-08-17D10,0001161,162,572Common, open-market saleForm 4 ↗
Charles RobbChief Business Officer2026-08-17D12500CommonForm 4 ↗
David L. MahoneyDirector2026-08-18D40012047,855Common, open-market saleForm 4 ↗
David L. MahoneyDirector2026-08-18D7,055119838,710Common, open-market saleForm 4 ↗
David L. MahoneyDirector2026-08-18D4,984117585,478Common, open-market saleForm 4 ↗
David L. MahoneyDirector2026-08-18D91,16711810,779,367Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-08-25D30,95500Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-25A30,95511351,339CommonForm 4 ↗
Sean MaduckSee Remarks2026-08-25D5,870126739,965Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-08-25D25,0851253,147,355Common, open-market saleForm 4 ↗
Kimberly ParkDirector2026-08-26D30,00000Derivative, Class A CommonForm 4 ↗
Kimberly ParkDirector2026-08-26D26,6851233,270,169Common, open-market saleForm 4 ↗
Kimberly ParkDirector2026-08-26D3,315122404,728CommonForm 4 ↗
Kimberly ParkDirector2026-08-26A30,00013404,700CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-01A13000CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-01A13011314,739CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-01A13800CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-01A13811315,646CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-01A16411318,594CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-09-01A13800CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-09-01A13811315,646CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01D25,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01A15000CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01A25,0008206,750CommonForm 4 ↗
William GuyerChief Development Officer2026-09-01A16400CommonForm 4 ↗
William GuyerChief Development Officer2026-09-01A16411318,594CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01D2,281116263,711Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-09-01D10,9891151,260,568Common, open-market saleForm 4 ↗
Charles RobbChief Business Officer2026-09-01A16400CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01A15011317,007CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-01D11,7301141,336,459Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D58,33300Derivative, Class A CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D23,6001092,580,674Common, open-market saleForm 4 ↗
Charles RobbChief Business Officer2026-09-02D9111310,318CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D23,7701112,631,349Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D10211311,565CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D1,537111171,181Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-02D721138,163CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D5,621115644,042Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D1,606114182,632Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D974112109,474Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02A58,333221,261,743CommonForm 4 ↗
Atabak MokariChief Financial Officer2026-09-02D10211311,565CommonForm 4 ↗
Sean MaduckSee Remarks2026-09-02D11711313,265CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-02D1,225115141,413Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14D2,59600Derivative, Class A CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14A2,5961129,465CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14D2,188114249,686Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14A7,40414100,398CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14D7,40400Derivative, Class A CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-09-14D7,812113885,261Common, open-market saleForm 4 ↗
James N. WilsonDirector2026-09-15D6,800110749,835Common, indirectForm 4 ↗
James N. WilsonDirector2026-09-15D40011144,335Common, indirectForm 4 ↗
James N. WilsonDirector2026-09-15D2,800112312,771Common, indirectForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-09-16D29610129,843CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-17A17,4938144,667CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-17D17,49300Derivative, Class A CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-24A5,00000CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-24A5,00000CommonForm 4 ↗
Charles RobbChief Business Officer2026-09-24D17,10000CommonForm 4 ↗
Sean MaduckSee Remarks2026-10-01D41300Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-10-01A41383,416CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-01D81000Derivative, Class A CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-01D81011593,473Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-01A8101410,984CommonForm 4 ↗
Sean MaduckSee Remarks2026-10-01D41311647,717Common, open-market saleForm 4 ↗
Justin Frederick GunnSee Remarks2026-10-01A100,00000Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-10-02D24,58700Derivative, Class A CommonForm 4 ↗
Sean MaduckSee Remarks2026-10-02D8,7441171,019,143Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-10-02D15,8431161,839,741Common, open-market saleForm 4 ↗
Sean MaduckSee Remarks2026-10-02A24,5878203,334CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-10-02D8,33300Derivative, Class A CommonForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-10-02D5,147117600,063Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-10-02D2,086116241,412Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-10-02D1,100115125,973Common, open-market saleForm 4 ↗
Roberto Wandenkolk VieiraPresident, Oncology2026-10-02A8,33322180,243CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02D5,83300Derivative, Class A CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02D3,35700Derivative, Class A CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02D4,744117552,869Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02D4,446116514,389Common, open-market saleForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02A5,83319112,344CommonForm 4 ↗
Joseph Douglas LyonSee Remarks2026-10-02A3,3571445,521CommonForm 4 ↗
James N. WilsonDirector2026-10-15D30011634,889Common, indirectForm 4 ↗
James N. WilsonDirector2026-10-15D3,046115351,476Common, indirectForm 4 ↗
James N. WilsonDirector2026-10-15D6,654114761,717Common, indirectForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Charles RobbOPTION2025-02-28——140,000—$5,163,087
Joseph BelanoffOPTION2025-02-28——350,000—12,907,718
William GuyerOPTION2025-02-28——140,000—5,163,087
Sean MaduckOPTION2025-02-28——140,000—5,163,087
Atabak MokariOPTION2025-02-28——140,000—5,163,087
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Charles Robb$0$0$5,163,0870.0%
Joseph Belanoff0012,907,7180.0%
William Guyer005,163,0870.0%
Sean Maduck005,163,0870.0%
Atabak Mokari005,163,0870.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
William GuyerOption110,83460.58—
Sean MaduckOption8,33419.26—
Sean MaduckOption4,16722.05—
Joseph BelanoffOption20,83419.26—
Sean MaduckOption58,33423.06—
Charles RobbRSU224—7,795
Sean MaduckOption108,33423.01—
Sean MaduckOption110,83460.58—
Charles RobbOption58,33423.06—
Atabak MokariOption4,16719.26—
Joseph BelanoffOption277,08460.58—
Atabak MokariOption58,33423.06—
Atabak MokariRSU178—6,194
Atabak MokariOption108,33423.01—
Atabak MokariRSU775—26,970
Charles RobbRSU997—34,696
Sean MaduckRSU888—30,902
Atabak MokariOption110,83460.58—
Charles RobbRSU292—10,162
Sean MaduckRSU266—9,257
Charles RobbRSU251—8,735
Atabak MokariRSU232—8,074
Charles RobbOption8,33419.26—
Sean MaduckRSU228—7,934
William GuyerRSU224—7,795
Sean MaduckRSU205—7,134
Atabak MokariRSU200—6,960
Joseph BelanoffOption145,83423.06—
Joseph BelanoffOption270,83423.01—
William GuyerOption4,16719.26—
William GuyerOption58,33423.06—
William GuyerOption108,33423.01—
Charles RobbOption108,33423.01—
Charles RobbOption110,83460.58—
05

Incentive-plan design — the Compensation Discussion & Analysis

The company aims to offer competitive compensation that rewards good short-term and long-term performance, aligning executive and stockholder interests. Because drug development takes many years, the largest portion of named executives' compensation consists of option grants with extended vesting periods to reward long-term stockholder value creation.

CEO STI target (% of salary)NaN%
CEO LTI target (% of salary)—
Independent consultant—
Clawback policy—
Anti-hedgingThe company has an insider trading policy that prohibits named executive officers and Board members from engaging in short sales and derivative securities related to the company's stock.
Anti-pledging—
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-2172,511,4294,560,385222,64394.08%Passed
20252025-06-1072,914,2934,195,859284,92394.56%Passed
20242024-05-1764,501,3721,018,089358,66698.45%Passed
20232023-05-1969,095,0251,450,799235,57097.62%Passed
20202020-05-2776,887,9755,808,900305,17992.98%Passed
20172017-05-2475,561,2674,089,35393,41994.87%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2194.08%a
20252025-06-1094.56%b
20242024-05-1798.45%c

a. Approved under the standard stated in the filing — “any shares abstained from voting " FOR " a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be counted in such nominee's favor and will have no effect on the outcome of the election.”.

b. Approved under the standard stated in the filing — “any shares abstained from voting " FOR " a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be counted in such nominee's favor and will have no effect on the outcome of the election.”.

c. Approved under the standard stated in the filing — “As a result, only " FOR " votes will affect the outcome, and any shares abstained from voting " FOR " a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be counted in such nominee's favor and will have no effect on the outcome of the election.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)46 : 1
CEO total compensation$15,303,551
Median employee compensation$334,040
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
James N. WilsonIndependent · Board Chair · Nominating/Governance$122,907—$1,170,007—$0$1,292,914
Gregg AltonIndependent · Audit · Compensation85,000—702,004—0787,004
David L. MahoneyIndependent · Audit · Compensation (Chair)82,500—702,004—0784,504
Gillian M. CannonIndependent · Audit · Departed during FY53,259—702,004—15,241770,504
G. Leonard Baker JrIndependent · Compensation · Nominating/Governance66,000—702,004—0768,004
Kimberly ParkIndependent · Audit · Nominating/Governance62,990—702,004—0764,994
Joshua M. MurrayIndependent · Audit62,500—702,004—0764,504
Daniel N. Swisher JrIndependent · Compensation60,000—702,004—0762,004
Joseph K. BelanoffEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$15,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000 / 12,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$595,156
Equity awards (grant-date value)$0
All other compensation$15,241
Total cost of the board$610,397

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Corcept Therapeutics2025Joseph Belanoff$1,182,333$0$12,907,718$0$15,303,551

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Corcept Therapeutics in fiscal 2025?
As disclosed, Joseph Belanoff (Chief Executive Officer and President) was the highest-paid executive at Corcept Therapeutics in fiscal 2025, with total compensation of $15,303,551.
What is Corcept Therapeutics's CEO-to-median employee pay ratio?
As disclosed, Corcept Therapeutics's CEO-to-median employee pay ratio was 46:1.
How did shareholders vote on Corcept Therapeutics's executive compensation?
As disclosed, 94.08% of shareholders supported Corcept Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Corcept Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Corcept Therapeutics reported total board compensation of $610,397 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Joseph BelanoffDEF 14A2026-04-170001628280-26-025735Section “Executive Compensation”. As printed: 15,303,551. Filing ↗machine: span 283504–283514
2Section 01, Charles RobbDEF 14A2026-04-170001628280-26-025735Section “Executive Compensation”. As printed: 6,380,500. Filing ↗machine: span 333502–333511
3Section 01, William GuyerDEF 14A2026-04-170001628280-26-025735Section “Executive Compensation”. As printed: 6,340,445. Filing ↗machine: span 296081–296090
4Section 01, Sean MaduckDEF 14A2026-04-170001628280-26-025735Section “Executive Compensation”. As printed: 6,208,642. Filing ↗machine: span 308454–308463
5Section 01, Atabak MokariDEF 14A2026-04-170001628280-26-025735Section “Executive Compensation”. As printed: 6,135,667. Filing ↗machine: span 320975–320984
6Section 03, Charles Robb OPTIONDEF 14A2026-04-170001628280-26-025735Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t17 · r14 · c13 · span 331671–331680
7Section 03, Joseph Belanoff OPTIONDEF 14A2026-04-170001628280-26-025735Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t17 · r2 · c13 · span 281411–281421
8Section 03, William Guyer OPTIONDEF 14A2026-04-170001628280-26-025735Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t17 · r5 · c13 · span 294263–294272
9Section 03, Sean Maduck OPTIONDEF 14A2026-04-170001628280-26-025735Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t17 · r8 · c13 · span 306623–306632
10Section 03, Atabak Mokari OPTIONDEF 14A2026-04-170001628280-26-025735Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t17 · r11 · c13 · span 319145–319154
11Section 07, pay ratioDEF 14A2026-04-170001628280-26-025735Section “CEO Pay Ratio”. As printed: 46 : 1. Filing ↗machine: span 653452–653462
12Section 08, James N. WilsonDEF 14A2026-04-170001628280-26-025735Section “Director Compensation”. As printed: 1,292,914. Filing ↗machine: span 784977–785111
13Section 08, Gregg AltonDEF 14A2026-04-170001628280-26-025735Section “Director Compensation”. As printed: 787,004. Filing ↗machine: span 787699–787831
14Section 08, David L. MahoneyDEF 14A2026-04-170001628280-26-025735Section “Director Compensation”. As printed: 784,504. Filing ↗machine: span 795986–796118
15Section 08, Gillian M. CannonDEF 14A2026-04-170001628280-26-025735Section “Director Compensation”. As printed: 770,504. Filing ↗machine: span 793290–793422
16Section 08, G. Leonard Baker JrDEF 14A2026-04-170001628280-26-025735Section “Director Compensation”. As printed: 768,004. Filing ↗machine: span 790400–790532
17Section 08, Kimberly ParkDEF 14A2026-04-170001628280-26-025735Section “Director Compensation”. As printed: 764,994. Filing ↗machine: span 801375–801507
18Section 08, Joshua M. MurrayDEF 14A2026-04-170001628280-26-025735Section “Director Compensation”. As printed: 764,504. Filing ↗machine: span 798682–798814
19Section 08, Daniel N. Swisher JrDEF 14A2026-04-170001628280-26-025735Section “Director Compensation”. As printed: 762,004. Filing ↗machine: span 804077–804209
20Section 08, Joseph K. BelanoffDEF 14A2026-04-170001628280-26-025735Section “Director Compensation”. As printed: 0. Filing ↗
21Section 02, Charles Robb 2026-05-13Form 42026-05-150001193125-26-227411Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Charles Robb 2026-05-13Form 42026-05-150001193125-26-227411Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Charles Robb 2026-05-13Form 42026-05-150001193125-26-227411Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Joshua M. Murray 2026-05-21Form 42026-05-260001193125-26-239699Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Daniel N. Swisher Jr 2026-05-21Form 42026-05-260001193125-26-239705Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, James N. Wilson 2026-05-21Form 42026-05-260001193125-26-239707Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Gregg Alton 2026-05-21Form 42026-05-260001193125-26-239714Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, G. Leonard Baker Jr 2026-05-21Form 42026-05-260001201715-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Kimberly Park 2026-05-21Form 42026-05-260001193125-26-239683Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, David L. Mahoney 2026-05-21Form 42026-05-260001193125-26-239691Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, James N. Wilson 2026-05-27Form 42026-05-290001193125-26-248953Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Charles Robb 2026-05-27Form 42026-07-080001193125-26-298871Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Sean Maduck 2026-05-27Form 42026-05-290001193125-26-248967Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, James N. Wilson 2026-05-27Form 42026-05-290001193125-26-248953Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Joseph Douglas Lyon 2026-05-27Form 42026-05-290001193125-26-248977Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, James N. Wilson 2026-05-27Form 42026-05-290001193125-26-248953Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Sean Maduck 2026-05-27Form 42026-05-290001193125-26-248967Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Sean Maduck 2026-05-27Form 42026-05-290001193125-26-248967Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Sean Maduck 2026-05-27Form 42026-05-290001193125-26-248967Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Joseph K. Belanoff 2026-05-29Form 42026-06-020001193125-26-253459Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Joseph K. Belanoff 2026-05-29Form 42026-06-020001193125-26-253459Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Joseph K. Belanoff 2026-05-29Form 42026-06-020001193125-26-253459Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Joseph K. Belanoff 2026-06-01Form 42026-06-020001193125-26-253459Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Charles Robb 2026-06-01Form 42026-06-030001193125-26-256002Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Atabak Mokari 2026-06-01Form 42026-06-030001193125-26-256011Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Atabak Mokari 2026-06-01Form 42026-06-030001193125-26-256011Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Sean Maduck 2026-06-01Form 42026-06-030001193125-26-256013Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Atabak Mokari 2026-06-01Form 42026-06-030001193125-26-256011Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Sean Maduck 2026-06-01Form 42026-06-030001193125-26-256013Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Sean Maduck 2026-06-01Form 42026-06-030001193125-26-256013Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, William Guyer 2026-06-01Form 42026-06-030001193125-26-256015Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Joseph Douglas Lyon 2026-06-01Form 42026-06-030001193125-26-256022Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Atabak Mokari 2026-06-01Form 42026-06-030001193125-26-256011Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Atabak Mokari 2026-06-01Form 42026-06-030001193125-26-256011Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Sean Maduck 2026-06-01Form 42026-06-030001193125-26-256013Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, William Guyer 2026-06-01Form 42026-06-030001193125-26-256015Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Joseph Douglas Lyon 2026-06-01Form 42026-06-030001193125-26-256022Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Sean Maduck 2026-06-01Form 42026-06-030001193125-26-256013Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Sean Maduck 2026-06-01Form 42026-06-030001193125-26-256013Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Charles Robb 2026-06-01Form 42026-06-030001193125-26-256002Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Atabak Mokari 2026-06-02Form 42026-06-030001193125-26-256011Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Sean Maduck 2026-06-02Form 42026-06-030001193125-26-256013Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, William Guyer 2026-06-02Form 42026-06-040001193125-26-257618Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Charles Robb 2026-06-02Form 42026-06-030001193125-26-256002Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Joseph Douglas Lyon 2026-06-02Form 42026-06-030001193125-26-256022Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, William Guyer 2026-06-02Form 42026-06-040001193125-26-257618Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, William Guyer 2026-06-02Form 42026-06-040001193125-26-257618Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Atabak Mokari 2026-06-15Form 42026-06-170001193125-26-274224Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Atabak Mokari 2026-06-15Form 42026-06-170001193125-26-274224Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Atabak Mokari 2026-06-15Form 42026-06-170001193125-26-274224Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Atabak Mokari 2026-06-15Form 42026-06-170001193125-26-274224Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Atabak Mokari 2026-06-15Form 42026-06-170001193125-26-274224Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Atabak Mokari 2026-06-15Form 42026-06-170001193125-26-274224Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, James N. Wilson 2026-06-16Form 42026-06-180001193125-26-275964Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, James N. Wilson 2026-06-16Form 42026-06-180001193125-26-275964Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, David L. Mahoney 2026-06-17Form 42026-06-180001193125-26-275963Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Sean Maduck 2026-07-01Form 42026-07-060001193125-26-296296Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Sean Maduck 2026-07-01Form 42026-07-060001193125-26-296296Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Sean Maduck 2026-07-01Form 42026-07-060001193125-26-296296Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Sean Maduck 2026-07-01Form 42026-07-060001193125-26-296296Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Sean Maduck 2026-07-01Form 42026-07-060001193125-26-296296Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, William Guyer 2026-07-07Form 42026-07-080001193125-26-298865Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, William Guyer 2026-07-07Form 42026-07-080001193125-26-298865Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, William Guyer 2026-07-07Form 42026-07-080001193125-26-298865Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, William Guyer 2026-07-07Form 42026-07-080001193125-26-298865Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Atabak Mokari 2026-07-15Form 42026-07-170001193125-26-308058Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Atabak Mokari 2026-07-15Form 42026-07-170001193125-26-308058Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Atabak Mokari 2026-07-15Form 42026-07-170001193125-26-308058Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Atabak Mokari 2026-07-15Form 42026-07-170001193125-26-308058Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Atabak Mokari 2026-07-15Form 42026-07-170001193125-26-308058Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, James N. Wilson 2026-07-15Form 42026-07-170001193125-26-308061Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, James N. Wilson 2026-07-15Form 42026-07-170001193125-26-308061Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Atabak Mokari 2026-07-15Form 42026-07-170001193125-26-308058Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Atabak Mokari 2026-07-15Form 42026-07-170001193125-26-308058Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Atabak Mokari 2026-07-15Form 42026-07-170001193125-26-308058Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, James N. Wilson 2026-07-15Form 42026-07-170001193125-26-308061Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, James N. Wilson 2026-07-15Form 42026-07-170001193125-26-308061Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Atabak Mokari 2026-07-30Form 42026-08-030001193125-26-330668Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Joseph Douglas Lyon 2026-08-03Form 42026-08-050001193125-26-335605Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Sean Maduck 2026-08-03Form 42026-08-050001193125-26-335617Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Sean Maduck 2026-08-03Form 42026-08-050001193125-26-335617Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Sean Maduck 2026-08-03Form 42026-08-050001193125-26-335617Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, William Guyer 2026-08-04Form 42026-08-060001193125-26-338637Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, William Guyer 2026-08-04Form 42026-08-060001193125-26-338637Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, William Guyer 2026-08-04Form 42026-08-060001193125-26-338637Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, William Guyer 2026-08-10Form 42026-08-120001193125-26-346942Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, William Guyer 2026-08-10Form 42026-08-120001193125-26-346942Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Sean Maduck 2026-08-10Form 42026-08-120001193125-26-346951Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Sean Maduck 2026-08-10Form 42026-08-120001193125-26-346951Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Sean Maduck 2026-08-10Form 42026-08-120001193125-26-346951Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, William Guyer 2026-08-10Form 42026-08-120001193125-26-346942Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, William Guyer 2026-08-10Form 42026-08-120001193125-26-346942Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Charles Robb 2026-08-12Form 42026-08-140001193125-26-352428Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Charles Robb 2026-08-12Form 42026-08-140001193125-26-352428Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Charles Robb 2026-08-12Form 42026-08-140001193125-26-352428Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, James N. Wilson 2026-08-14Form 42026-08-180001193125-26-355562Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, James N. Wilson 2026-08-14Form 42026-08-180001193125-26-355562Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Sean Maduck 2026-08-14Form 42026-08-180001193125-26-355563Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, James N. Wilson 2026-08-14Form 42026-08-180001193125-26-355562Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Sean Maduck 2026-08-14Form 42026-08-180001193125-26-355563Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Sean Maduck 2026-08-14Form 42026-08-180001193125-26-355563Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Charles Robb 2026-08-17Form 42026-08-180001193125-26-355560Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Charles Robb 2026-08-17Form 42026-08-180001193125-26-355560Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, David L. Mahoney 2026-08-18Form 42026-08-200001193125-26-359255Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, David L. Mahoney 2026-08-18Form 42026-08-200001193125-26-359255Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, David L. Mahoney 2026-08-18Form 42026-08-200001193125-26-359255Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, David L. Mahoney 2026-08-18Form 42026-08-200001193125-26-359255Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Sean Maduck 2026-08-25Form 42026-08-270001193125-26-371388Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Sean Maduck 2026-08-25Form 42026-08-270001193125-26-371388Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Sean Maduck 2026-08-25Form 42026-08-270001193125-26-371388Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Sean Maduck 2026-08-25Form 42026-08-270001193125-26-371388Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Kimberly Park 2026-08-26Form 42026-08-280001193125-26-374607Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Kimberly Park 2026-08-26Form 42026-08-280001193125-26-374607Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Kimberly Park 2026-08-26Form 42026-08-280001193125-26-374607Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Kimberly Park 2026-08-26Form 42026-08-280001193125-26-374607Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Joseph Douglas Lyon 2026-09-01Form 42026-09-030001193125-26-382450Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Joseph Douglas Lyon 2026-09-01Form 42026-09-030001193125-26-382450Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Roberto Wandenkolk Vieira 2026-09-01Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Roberto Wandenkolk Vieira 2026-09-01Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Charles Robb 2026-09-01Form 42026-09-030001193125-26-382457Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Atabak Mokari 2026-09-01Form 42026-09-030001193125-26-382463Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Atabak Mokari 2026-09-01Form 42026-09-030001193125-26-382463Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Sean Maduck 2026-09-01Form 42026-09-030001193125-26-382474Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Sean Maduck 2026-09-01Form 42026-09-030001193125-26-382474Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Sean Maduck 2026-09-01Form 42026-09-030001193125-26-382474Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, William Guyer 2026-09-01Form 42026-09-030001193125-26-382475Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, William Guyer 2026-09-01Form 42026-09-030001193125-26-382475Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Sean Maduck 2026-09-01Form 42026-09-030001193125-26-382474Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Sean Maduck 2026-09-01Form 42026-09-030001193125-26-382474Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Charles Robb 2026-09-01Form 42026-09-030001193125-26-382457Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Sean Maduck 2026-09-01Form 42026-09-030001193125-26-382474Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Sean Maduck 2026-09-01Form 42026-09-030001193125-26-382474Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Roberto Wandenkolk Vieira 2026-09-02Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Roberto Wandenkolk Vieira 2026-09-02Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Charles Robb 2026-09-02Form 42026-09-030001193125-26-382457Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Roberto Wandenkolk Vieira 2026-09-02Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Roberto Wandenkolk Vieira 2026-09-02Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Roberto Wandenkolk Vieira 2026-09-02Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Joseph Douglas Lyon 2026-09-02Form 42026-09-030001193125-26-382450Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Roberto Wandenkolk Vieira 2026-09-02Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Roberto Wandenkolk Vieira 2026-09-02Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Roberto Wandenkolk Vieira 2026-09-02Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Roberto Wandenkolk Vieira 2026-09-02Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Atabak Mokari 2026-09-02Form 42026-09-030001193125-26-382463Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, Sean Maduck 2026-09-02Form 42026-09-030001193125-26-382474Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, Roberto Wandenkolk Vieira 2026-09-02Form 42026-09-030001193125-26-382456Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Joseph Douglas Lyon 2026-09-14Form 42026-09-160001193125-26-393125Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Joseph Douglas Lyon 2026-09-14Form 42026-09-160001193125-26-393125Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Joseph Douglas Lyon 2026-09-14Form 42026-09-160001193125-26-393125Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Joseph Douglas Lyon 2026-09-14Form 42026-09-160001193125-26-393125Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, Joseph Douglas Lyon 2026-09-14Form 42026-09-160001193125-26-393125Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Joseph Douglas Lyon 2026-09-14Form 42026-09-160001193125-26-393125Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, James N. Wilson 2026-09-15Form 42026-09-160001193125-26-393124Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, James N. Wilson 2026-09-15Form 42026-09-160001193125-26-393124Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, James N. Wilson 2026-09-15Form 42026-09-160001193125-26-393124Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Roberto Wandenkolk Vieira 2026-09-16Form 42026-09-180001193125-26-395837Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Charles Robb 2026-09-17Form 42026-09-180001193125-26-395827Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Charles Robb 2026-09-17Form 42026-09-180001193125-26-395827Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Charles Robb 2026-09-24Form 42026-09-280001193125-26-405402Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, Charles Robb 2026-09-24Form 42026-09-280001193125-26-405402Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, Charles Robb 2026-09-24Form 42026-09-280001193125-26-405402Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, Sean Maduck 2026-10-01Form 42026-10-050001193125-26-414674Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, Sean Maduck 2026-10-01Form 42026-10-050001193125-26-414674Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, Joseph Douglas Lyon 2026-10-01Form 42026-10-050001193125-26-414684Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, Joseph Douglas Lyon 2026-10-01Form 42026-10-050001193125-26-414684Insider equity transaction reported since the proxy statement. Filing ↗
200Section 02, Joseph Douglas Lyon 2026-10-01Form 42026-10-050001193125-26-414684Insider equity transaction reported since the proxy statement. Filing ↗
201Section 02, Sean Maduck 2026-10-01Form 42026-10-050001193125-26-414674Insider equity transaction reported since the proxy statement. Filing ↗
202Section 02, Justin Frederick Gunn 2026-10-01Form 42026-10-050001193125-26-414667Insider equity transaction reported since the proxy statement. Filing ↗
203Section 02, Sean Maduck 2026-10-02Form 42026-10-050001193125-26-414674Insider equity transaction reported since the proxy statement. Filing ↗
204Section 02, Sean Maduck 2026-10-02Form 42026-10-050001193125-26-414674Insider equity transaction reported since the proxy statement. Filing ↗
205Section 02, Sean Maduck 2026-10-02Form 42026-10-050001193125-26-414674Insider equity transaction reported since the proxy statement. Filing ↗
206Section 02, Sean Maduck 2026-10-02Form 42026-10-050001193125-26-414674Insider equity transaction reported since the proxy statement. Filing ↗
207Section 02, Roberto Wandenkolk Vieira 2026-10-02Form 42026-10-050001193125-26-414688Insider equity transaction reported since the proxy statement. Filing ↗
208Section 02, Roberto Wandenkolk Vieira 2026-10-02Form 42026-10-050001193125-26-414688Insider equity transaction reported since the proxy statement. Filing ↗
209Section 02, Roberto Wandenkolk Vieira 2026-10-02Form 42026-10-050001193125-26-414688Insider equity transaction reported since the proxy statement. Filing ↗
210Section 02, Roberto Wandenkolk Vieira 2026-10-02Form 42026-10-050001193125-26-414688Insider equity transaction reported since the proxy statement. Filing ↗
211Section 02, Roberto Wandenkolk Vieira 2026-10-02Form 42026-10-050001193125-26-414688Insider equity transaction reported since the proxy statement. Filing ↗
212Section 02, Joseph Douglas Lyon 2026-10-02Form 42026-10-050001193125-26-414684Insider equity transaction reported since the proxy statement. Filing ↗
213Section 02, Joseph Douglas Lyon 2026-10-02Form 42026-10-050001193125-26-414684Insider equity transaction reported since the proxy statement. Filing ↗
214Section 02, Joseph Douglas Lyon 2026-10-02Form 42026-10-050001193125-26-414684Insider equity transaction reported since the proxy statement. Filing ↗
215Section 02, Joseph Douglas Lyon 2026-10-02Form 42026-10-050001193125-26-414684Insider equity transaction reported since the proxy statement. Filing ↗
216Section 02, Joseph Douglas Lyon 2026-10-02Form 42026-10-050001193125-26-414684Insider equity transaction reported since the proxy statement. Filing ↗
217Section 02, Joseph Douglas Lyon 2026-10-02Form 42026-10-050001193125-26-414684Insider equity transaction reported since the proxy statement. Filing ↗
218Section 02, James N. Wilson 2026-10-15Form 42026-10-160001193125-26-424350Insider equity transaction reported since the proxy statement. Filing ↗
219Section 02, James N. Wilson 2026-10-15Form 42026-10-160001193125-26-424350Insider equity transaction reported since the proxy statement. Filing ↗
220Section 02, James N. Wilson 2026-10-15Form 42026-10-160001193125-26-424350Insider equity transaction reported since the proxy statement. Filing ↗
221Section 06, 2026 voteForm 8-K2026-05-280001628280-26-038793Item 5.07 · say-on-pay result. As reported: 94.08% (votes for as printed: 72,511,429). Filing ↗
222Section 06, 2025 voteForm 8-K2025-06-160001628280-25-031624Item 5.07 · say-on-pay result. As reported: 94.56% (votes for as printed: 72,914,293). Filing ↗
223Section 06, 2024 voteForm 8-K2024-05-230001628280-24-024936Item 5.07 · say-on-pay result. As reported: 98.45% (votes for as printed: 64,501,372). Filing ↗
224Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
225Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
226Section 09b board cost (computed)Computed——Cash 595,156 + equity 0 + all other 15,241 = 610,397, summed across the director compensation table rows.machine: formula: Σ = 610,397
227Corcept Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-170001628280-26-025735CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.